FDA granted full approval to Travere Therapeutics’ drug FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. The approval, announced on April 13, 2026, makes FILSPARI the first FDA‑approved therapy for this rare kidney disease and extends its indication beyond the previously approved use for IgA nephropathy.
The decision was based on the Phase 3 DUPLEX study, which demonstrated a 48 % reduction in proteinuria at 108 weeks in patients without nephrotic syndrome compared with a 27 % reduction with irbesartan. The study also reported a modest 1.1 mL/min/1.73 m² improvement in estimated glomerular filtration rate and confirmed a safety profile comparable to irbesartan, with no new safety concerns.
The approval expands FILSPARI’s addressable market to more than 30,000 U.S. patients with FSGS who do not have nephrotic syndrome, potentially doubling the company’s revenue opportunity. Travere’s management highlighted that the new indication adds to the 100,000‑plus U.S. patient population that includes both FSGS and IgA nephropathy, underscoring the drug’s broader impact.
Travere’s financial performance in the year to 2025 showed strong growth, with FILSPARI sales reaching $322 million and a narrowed net loss compared with 2024. The company’s ability to scale the drug’s commercial footprint, supported by its Travere TotalCare patient‑support program, positions it to capture the expanded market quickly.
Market reaction to the approval was robust. Shares surged more than 34 % on the day following the announcement, reflecting investor confidence in the first‑in‑class status and the sizable market opportunity. Analysts noted that the approval removes a significant unmet need and could generate an estimated $1 billion in annual revenue for Travere.
CEO Eric Dube emphasized the significance of the milestone, stating, “This approval reflects years of perseverance and our belief that those living with FSGS deserve better. It also builds on our leadership and progress in rare kidney diseases, expanding FILSPARI’s potential reach to more than 100,000 people in the U.S. with FSGS and IgAN who need better treatment options.” The statement highlights the company’s confidence in the drug’s commercial prospects.
The approval also confirms FILSPARI’s safety profile, with a boxed warning for hepatotoxicity and embryo‑fetal toxicity, and the drug remains available only through the FILSPARI REMS program. The dual endothelin‑A and angiotensin‑II receptor antagonist mechanism underpins the clinical benefits observed in the DUPLEX study.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.